Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Low fibrinogen alone did not prevent arterial thrombosis in humans or mice, but loss of the fibrinogen αC region reduced clot formation. The study suggests fibrinogen structure, not just level, influences arterial thrombotic risk.
A large EBMT registry study suggests that escalating fludarabine during lymphodepletion does not improve tisagenlecleucel outcomes in LBCL and may worsen survival, while axicabtagene ciloleucel retains superior efficacy at standard dosing b
Patients with primary cancer who had pre-diagnostic CHIP faced a higher risk of second cancers, especially blood cancers. The findings suggest CHIP may help identify survivors who need closer long-term monitoring.
A new Blood study links relapse after myeloma ASCT to CSF-1R+ immunosuppressive marrow macrophages and shows that CSF-1R inhibition synergizes with lenalidomide in preclinical models, providing a strong translational rationale for post-tran
Extended follow-up from ASTRUM-005 shows serplulimab plus chemotherapy improves long-term survival in untreated extensive-stage small cell lung cancer, with manageable safety and encouraging patient-reported outcomes.
A phase 1 study suggests non-gene-edited allogeneic CD19 CAR-T therapy can induce remissions in relapsed or refractory B-ALL without observed GVHD, though durability remains limited and larger trials are needed.
Immune checkpoint therapy has become a major advance in pediatric Hodgkin lymphoma and is now being actively tested across selected pediatric non-Hodgkin lymphomas with strong PD-L1 biology.
Mouse and human observational data suggest that the fibrinogen αC region is a key determinant of arterial thrombosis under hypofibrinogenemic conditions, likely through platelet GPVI-dependent mechanisms.
A small pilot study found that busulfan-based haploidentical stem cell transplantation followed by dinutuximab beta was feasible and may improve long-term remission in very high-risk neuroblastoma.
Preclinical data suggest fingolimod and mocravimod can resensitize NRAS-mutated FLT3-ITD AML to FLT3 inhibitors by suppressing ERK-SPHK1-AKT signaling, including activity in patient blasts and an orthotopic mouse model.
The AHA-proposed CRIS classification reclassified many cancer-associated strokes previously labeled cryptogenic and identified a subgroup with markedly worse survival, improving both etiologic clarity and prognostic stratification.
Early immune profiling after allogeneic stem cell transplant was linked to survival and relapse risk. Stronger innate and adaptive immune recovery predicted better outcomes, while certain activation and checkpoint markers were associated wi
A phase I/II study suggests twice-weekly ixazomib plus pomalidomide-dexamethasone is a feasible all-oral option in relapsed/refractory multiple myeloma, with a 65.8% response rate at the RP2D and manageable hematologic toxicity.
A study of 91 B-ALL patients found that relapse after CD19/CD22 dual-target CAR T-cell therapy is mainly driven by CAR T-cell functional failure and antigen loss, with PAX5 mutations linked to early immune escape.
A phase 1 trial suggests briquilimab can be safely added to nonmyeloablative conditioning before allogeneic transplant in older adults with high-risk AML or MDS, with biologic evidence of hematopoietic stem/progenitor cell depletion and enc
The 2024 EBMT activity report marks a major cellular therapy milestone, showing record allogeneic HCT, continued CAR-T expansion, and persistent disparities in donor use, pediatric activity, and country-level access.
EBMT’s 2024 report marks over one million reported stem cell transplants and continued rapid CAR-T growth, highlighting shifts in indications, donor use, and access across Europe.
A low-cost NGS-based MRD test detected hidden AML cells before transplant and strongly predicted worse survival after allogeneic stem cell transplantation.
miR-28 suppresses the emergence of ibrutinib resistance in ABC-DLBCL by disrupting clonal selection and dampening mitochondrial and mTOR signaling, with promising preclinical nanoparticle delivery results.
A study of leukemia patients found that Orca-T transplant therapy increases a regulatory-like CD4+FOXP3+Helios+ T-cell subset early after treatment, and this subset correlates with later T-cell activation, offering a potential biomarker for
Open language-specific specialty feeds and department pages.